How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

22,549 results for

Hypertension in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Applying a “Big Data” Literature System to Recommend Antihypertensive Drugs for Hypertension Patients with Diabetes Mellitus Full Text available with Trip Pro

over time. Sensitivity was better than specificity for MedRank; in addition, sensitivity was maintained at a high level, and specificity increased from 1997 to 2013. CONCLUSIONS The use of MedRank in ranking medical literature on hypertension with diabetes mellitus in our study suggests possible application in clinical practice; it is a potential method for supporting antihypertensive drug-prescription decisions. (...) Applying a “Big Data” Literature System to Recommend Antihypertensive Drugs for Hypertension Patients with Diabetes Mellitus BACKGROUND The explosive increase in medical literature has changed therapeutic strategies, but it is challenging for physicians to keep up-to-date on the medical literature. Scientific literature data mining on a large-scale of can be used to refresh physician knowledge and better improve the quality of disease treatment. MATERIAL AND METHODS This paper reports

2018 Medical science monitor : international medical journal of experimental and clinical research

2. Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. (Abstract)

Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan. We conducted a post-trial study, the Candesartan Antihypertensive Survival Evaluation in Japan 10-year follow-up (CASE-J 10). This study aimed (...) %), and when adjusted for clinical factors, candesartan remained an independent predictor for NOD prevention (hazard ratioadj = 0.71, 95% CI 0.52-0.98).With more than 28 385 patient-years follow-up, we demonstrated that candesartan and amlodipine were comparable in reducing cardiovascular events in patients with high-risk hypertension. Additionally, our results may support candesartan's superiority in reducing NOD incidence compared with amlodipine even after the long-term follow-up.

2018 Journal of Hypertension

3. Treatment of Hypertension in Association With Diabetes Mellitus

with significant elevations in blood pressure. Caution, however, should be exercised in patients in whom a substantial fall in BP is more likely to occur or is more poorly tolerated (e.g., the elderly and patients with autonomic neuropathy). Regarding systolic BP targets, two major meta-analyses have examined the relative benefits and risks of achieving lower SBP in patients with diabetes mellitus and hypertension. The Bangalore et al. meta-analysis included trials comparing achieved SBP levels of < 135 mm Hg (...) complications (e.g., retinopathy and nephropathy), as well as macrovascular complications in patients with hypertension, who have diabetes mellitus. The association between BP level (systolic and diastolic) and cardiovascular risk is continuous and graded in patients with diabetes mellitus. Treatment of hypertension appears to confer greater benefits in people with diabetes than in age-matched people with hypertension, who do not have diabetes , and the benefits of aggressive blood pressure lowering may

2018 Hypertension Canada

4. Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. Full Text available with Trip Pro

Comparing six antihypertensive medication classes for preventing new-onset diabetes mellitus among hypertensive patients: a network meta-analysis. Hypertensive patients usually have a higher risk of new-onset diabetes mellitus (NOD) which may trigger cardiovascular diseases. In this study, the effectiveness of six antihypertensive agents with respect to NOD prevention in hypertensive patients was assessed. A network meta-analysis was conducted to compare the efficacy of specific drug classes (...) , were preferable for NOD prevention in hypertensive patients. Hydrochlorothiazide also exhibited a reliable performance in comparison with other agents.© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

2017 Journal of cellular and molecular medicine

5. Intervention for High-normal or Borderline-elevated Blood Pressure in Adults With Type 2 Diabetes

Status : Not yet recruiting First Posted : August 29, 2017 Last Update Posted : January 12, 2018 See Sponsor: Jiyan Chen Information provided by (Responsible Party): Jiyan Chen, Guangdong General Hospital Study Details Study Description Go to Brief Summary: Lowering of blood pressure (BP) in high-risk hypertensive individuals reduces major adverse cardiovascular (CV) events. Diabetic patients with hypertension benefit from BP lowering treatment. The present trial,IPAD in brief, is a randomized (...) Intervention for High-normal or Borderline-elevated Blood Pressure in Adults With Type 2 Diabetes Intervention for High-normal or Borderline-elevated Blood Pressure in Adults With Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2017 Clinical Trials

6. Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension

Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension 1 Translation of the executive summary of the final report Proteomanalyse im Urin zur Erkennung einer diabetischen Nephropathie bei Patientinnen und Patienten mit Diabetes mellitus und arteriellem Hypertonus (Version 1.0; Status: 17 September 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. D13-01 Urinary proteome analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension 1 Executive summary of final report D13-01 Version 1.0 Proteome analysis for detection of DN 17 September 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension Full Text available with Trip Pro

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension Empagliflozin, a sodium-glucose cotransporter 2 inhibitor indicated for type 2 diabetes mellitus (T2DM), can lower blood pressure (BP) and reduce cardiovascular mortality in patients with T2DM and preexisting cardiovascular disease. Its effects in blacks have been understudied.In this 24-week study, 150 blacks with T2DM and hypertension had glycohemoglobin (primary end (...) to -3.04; P=0.0025], respectively). Diastolic BP was also reduced.In blacks with T2DM, empagliflozin reduced glycohemoglobin, body weight, and BP. The effect of empagliflozin on BP increased from 12 to 24 weeks, suggesting a full antihypertensive effect takes ≥6 months to be fully realized. At week 24, the placebo-subtracted BP effect was similar to standard antihypertensive monotherapies, suggesting that empagliflozin may be beneficial for this high-risk population.URL: https://www.clinicaltrials.gov

2019 EvidenceUpdates

8. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Full Text available with Trip Pro

Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. In November 2017, the American College of Cardiology (ACC) and the American Heart Association (AHA) released a clinical practice guideline for the prevention, detection, evaluation, and treatment of high blood pressure (BP) in adults. This article summarizes the major recommendations.In 2014, the ACC (...) and the AHA appointed a multidisciplinary committee to update previous reports of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The committee reviewed literature and commissioned systematic reviews and meta-analyses on out-of-office BP monitoring, the optimal target for BP lowering, the comparative benefits and harms of different classes of antihypertensive agents, and the comparative benefits and harms of initiating therapy with a single

2018 Annals of Internal Medicine

9. Maternal Diabetes Mellitus as a Risk Factor for High Blood Pressure in Late Childhood. Full Text available with Trip Pro

Maternal Diabetes Mellitus as a Risk Factor for High Blood Pressure in Late Childhood. Intrauterine fetal conditions can have lifelong cardiovascular effects. The impact of maternal diabetes mellitus on children's cardiovascular profile is not well established. The goal of this study was to explore the association between maternal diabetes mellitus and offspring's blood pressure (BP) ≤10 years of age. Generation XXI is a prospective birth cohort, which enrolled 8301 mother-offspring pairs (...) in the mechanisms of BP prenatal programing. Our results provide further evidence that maternal diabetes mellitus is associated with high BP late in childhood, demonstrating a significant role of child's body mass in the pathway of this association.

2019 Hypertension

10. Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension Full Text available with Trip Pro

Antihypertensive effect of an enzymatic hydrolysate from Styela clava flesh tissue in type 2 diabetic patients with hypertension In this randomized, placebo-controlled, double-blind study, we evaluated the antihypertensive effects of enzymatic hydrolysate from Styela clava flesh tissue in patients with type 2 diabetes mellitus (T2DM) and hypertension.S. clava flesh tissue hydrolysate (SFTH) (n = 34) and placebo (n = 22) were randomly allocated to the study subjects. Each subject ingested two (...) test capsules (500 mg) containing powdered SFTH (SFTH group) or placebo capsules (placebo group) during four weeks.In the SFTH group, systolic and diastolic blood pressure decreased significantly 4 weeks after ingestion by 9.9 mmHg (P < 0.01) and 7.8 mmHg (P < 0.01), respectively. In addition, the SFTH group exhibited a significant decrease in hemoglobin A1c with a tendency toward improvement in homeostasis model assessment of insulin resistance, triglyceride, apolipoprotein B and plasma insulin

2017 Nutrition research and practice Controlled trial quality: uncertain

11. The Rates of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Patients With Diabetes Mellitus

With Diabetes Mellitus Actual Study Start Date : April 1, 2017 Actual Primary Completion Date : June 30, 2017 Actual Study Completion Date : June 30, 2017 Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Overtreatment for glycemia [ Time Frame: 7 days ] HbA1c<6.5% plus use of ≥2 oral hypoglycemics or insulin, except metformine. Secondary Outcome Measures : Undertreatment for glycemia [ Time Frame: 7 days ] HbA1c>9% Overtreatment for blood pressure [ Time Frame: 7 days ] systolic (...) The Rates of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Patients With Diabetes Mellitus The Rates of Overtreatment and Deintensification in Patients With Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2018 Clinical Trials

12. Novel augmented reality solution for improving health literacy around antihypertensives in people living with type 2 diabetes mellitus: protocol of a technology evaluation study. Full Text available with Trip Pro

Novel augmented reality solution for improving health literacy around antihypertensives in people living with type 2 diabetes mellitus: protocol of a technology evaluation study. Low health literacy is common in people with type 2 diabetes mellitus (T2DM) (up to 40%), associated with decreased self-efficacy in managing T2DM and its important complications, mainly hypertension. This study introduces, for the first time, an easy-to-use solution based on augmented reality (AR) on smartphones (...) , to enhance health literacy around antihypertensive medicines. It assesses the feasibility of the solution for improving health literacy, oriented specifically to angiotensin II receptor blockers; embedding the health literacy improvement into the use cycle of angiotensin II receptor blockers and providing continuous access to information as a form of patient engagement.This is a technology evaluation study with one technology group (AR plus usual care) and one non-technology group (usual care). Both

2018 BMJ open

13. [Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension]

[Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension] Proteomanalyse im urin zur erkennung einer diabetischen nephropathie bei patientinnen und patienten mit diabetes mellitus und arteriellem hypertonus [Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension] Proteomanalyse im urin zur erkennung einer diabetischen nephropathie bei patientinnen und (...) patienten mit diabetes mellitus und arteriellem hypertonus [Urine proteomic analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Proteomanalyse im urin zur erkennung einer diabetischen nephropathie bei patientinnen und patienten mit

2016 Health Technology Assessment (HTA) Database.

14. Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial. Full Text available with Trip Pro

Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial. Based on non-clinical data, it is expected that azilsartan, an angiotensin II receptor blocker, will help improve insulin resistance in addition to its hypotensive action. The present study is aimed to explore the effect of azilsartan compared to telmisartan on insulin sensitivity in hypertensive patients (...) pressure were observed at week 4 and the reduced levels were maintained throughout the treatment period in both groups. No serious treatment-emergent adverse events (TEAEs) were observed. Only one drug-related TEAE (mild decrease in blood pressure) was reported in one patient in the azilsartan group.Neither azilsartan nor telmisartan had any clinically remarkable effects on insulin resistance parameters when administered for 12 weeks to patients with grade I or II essential hypertension and coexisting

2019 PLoS ONE Controlled trial quality: uncertain

15. Effectiveness of primary healthcare educational interventions undertaken by nurses to improve chronic disease management in patients with diabetes mellitus, hypertension and hypercholesterolemia: A systematic review (Abstract)

care centres in order to improve control and chronic disease management in Type 2 diabetes mellitus, hypertension and hypercholesterolemia.Out of the 20 studies included in the systematic review, one had a low risk of bias, 14 an uncertain risk of bias, and five a high risk of bias. Although several studies showed significant changes in the measured variables, few significant differences were maintained over time, observed only in metabolic indicators and clinical variables more than in lifestyle (...) Effectiveness of primary healthcare educational interventions undertaken by nurses to improve chronic disease management in patients with diabetes mellitus, hypertension and hypercholesterolemia: A systematic review Diabetes, hypertension and hypercholesterolemia are important chronic health problems that are becoming increasingly frequent worldwide. Educational interventions are a challenge for health teams. Nurses play a major role in overall health by providing educational interventions

2018 EvidenceUpdates

16. Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants. (Abstract)

Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants. Although guidelines recommend strict blood pressure (BP) control in patients with type 2 diabetes mellitus (T2DM) and elevated cardiovascular risk, the long-term effects of this approach are unknown. We investigated the effect of intensive BP control on clinical outcomes in patients with T2DM over 9 years of follow-up. We (...) included Action to Control Cardiovascular Risk in Diabetes - Blood Pressure participants in the standard glucose control arm who had established cardiovascular disease, chronic kidney disease, were ≥75 years of age or who had a 10-year coronary heart risk ≥15%. Participants were randomized to either intensive (systolic BP < 120 mm Hg) or standard (systolic BP < 140 mm Hg) BP control for an average of 5 years. Observational follow-up occurred for an average of 4 years thereafter. After an average total

2018 obesity & metabolism Controlled trial quality: predicted high

17. Potentially Inappropriate Prescribing in Older Adults with Hypertension or Diabetes Mellitus and Hypertension in a Primary Care Setting in Bahrain Full Text available with Trip Pro

Potentially Inappropriate Prescribing in Older Adults with Hypertension or Diabetes Mellitus and Hypertension in a Primary Care Setting in Bahrain The aims of this study were to evaluate: (1) the prevalence and types of potentially inappropriate prescribing in older adults with hypertension or diabetes mellitus and hypertension, and (2) whether or not differences in the training of primary care physicians were associated with potentially inappropriate prescribing.Primary care prescriptions (...) ). Of the 712 prescriptions, 543 (76.3%) were used for the treatment of acute medical illnesses. The most common examples of potentially inappropriate prescribing were: orphenadrine (n = 174; 8.33%), long-term nonsteroidal anti-inflammatory drugs for > 3 months (n = 150; 7.18%), proton pump inhibitors for > 8 weeks (n = 135; 6.46%), antihypertensive therapy duplication (n = 59; 2.82%), long-acting glyburide (n = 48; 2.29%), and chlordiazepoxide for > 1 month (n = 44; 2.11%). Family physicians showed

2018 Medical Principles and Practice

18. Correction: Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: A population-based cohort study. Full Text available with Trip Pro

Correction: Increased risk of ischemic heart disease, hypertension, and type 2 diabetes in women with previous gestational diabetes mellitus, a target group in general practice for preventive interventions: A population-based cohort study. [This corrects the article DOI: 10.1371/journal.pmed.1002488.].

2019 PLoS medicine

19. Associations between diabetes mellitus and pulmonary hypertension in chronic respiratory disease patients. Full Text available with Trip Pro

Associations between diabetes mellitus and pulmonary hypertension in chronic respiratory disease patients. Pulmonary hypertension (PH) is a common complication of chronic respiratory disease. Recent studies have reported diabetes mellitus (DM) to be a poor prognostic factor in patients with chronic respiratory disease, including chronic obstructive pulmonary disease or interstitial pneumoniae. However, the association between DM and PH in chronic respiratory disease remains unclear (...) . In this study, we aimed to investigate whether DM is a predictor of PH in patients with chronic respiratory disease.We prospectively analyzed 386 patients in our hospital with chronic respiratory disease. An echocardiographic pressure gradient between the right atrium and the right ventricle of ≥ 40 mmHg was defined as PH. We compared the clinical characteristics and impact of DM between chronic respiratory disease patients with and those without PH.Of the 386 patients, 42 (10.9%) were diagnosed as having

2018 PLoS ONE

20. Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus. Full Text available with Trip Pro

Fatty acid-binding protein 4 predicts gestational hypertension and preeclampsia in women with gestational diabetes mellitus. Fatty acid-binding protein 4 (FABP4) has been proposed to be a potential predictive factor of gestational hypertension or preeclampsia (GH/PE) because of its integrating metabolic and inflammatory responses. Women with gestational diabetes mellitus (GDM) are more likely to develop both GH/PE, than the normal population. The aim of our study was to examine the relationship (...) between plasma FABP4 in the second trimester of pregnancy and the risk of GH/PE in women with GDM.This was a nested case-control study conducted within a large on-going prospective cohort study conducted at Peking University First Hospital. A total of 1344 women, who were diagnosed with GDM, according to a 75 g oral glucose tolerance test, participated in the GDM One-Day Clinic at Peking University First Hospital from February 24, 2016 to February 9, 2017. Of the 748 GDM women who agreed to the blood

2018 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>